Lisiyao You
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Lisiyao You has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dong Fan
Department of General Surgery, Tangdu Hospital, Air Force Medical University, Xi’an 710038, China
1 shared publication - Guodong Li
College of Life Sciences, Northwest University, Xi’an 710069, China
1 shared publication - Huadong Zhao
Department of General Surgery, Tangdu Hospital, Air Force Medical University, China
1 shared publication - Shuangpeng Pu
College of Life Sciences, Northwest University, Xi’an 710069, China
1 shared publication - Xiyan Lu
Outpatient Department of the Second Affiliated Hospital of the Fourth Military Medical University, Xi’an 710032, China
1 shared publication - Yuan Gao
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an 710032, China
1 shared publication
Latest Publications
- Open Access
- 3 January 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (1) , 58
Innovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy
Outer membrane vesicles (OMVs) are double-layered structures of nanoscale lipids released by gram-negative bacteria. They have the same membrane composition and characteristics as primitive cells, which enables them to penetrate cells and tissues efficiently. These OMVs exhibit excellent membrane stability, immunogenicity, safety, and permeability (which makes it easier for them to penetrate into tumour tissue), making them suitable for developing cancer vaccines and drug delivery systems. Recent studies have focused on engineering OMVs to enhance tumour-targeting capabilities, reduce toxicity, and extend circulation time in vivo. This article reviews the latest progress in OMV engineering for tumour treatment and discusses the challenges associated with the use of OMV-based antitumour therapy in clinical practice.
- 3 January 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (1) , 58
Open AccessInnovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy
Outer membrane vesicles (OMVs) are double-layered structures of nanoscale lipids released by gram-negative bacteria. They have the same membrane composition and characteristics as primitive cells, which enables them to penetrate cells and tissues efficiently. These OMVs exhibit excellent membrane stability, immunogenicity, safety, and permeability (which makes it easier for them to penetrate into tumour tissue), making them suitable for developing cancer vaccines and drug delivery systems. Recent studies have focused on engineering OMVs to enhance tumour-targeting capabilities, reduce toxicity, and extend circulation time in vivo. This article reviews the latest progress in OMV engineering for tumour treatment and discusses the challenges associated with the use of OMV-based antitumour therapy in clinical practice.